Former Pharmaceutical Executive Joins Lymphoma Research Foundation Board of Directors
Former Pharmaceutical Executive Joins Lymphoma Research Foundation Board of Directors
On July 31, 2020 the U.S. Food and Drug Administration (FDA) announced it has approved tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, in combination with lenalidomide (REVLIMID) for adult patients with relapsed or refractory diffuse large B-cell lymphoma…